[Mucus production consequences in cystoplasties and continent urinary diversions in children--long term experiences].
P Zerhau, M Husár
https://pubmed.ncbi.nlm.nih.gov/16689148/Actively Recruiting
Led by Zhujiang Hospital · Updated on 2026-10-09
96
Participants Needed
1
Research Sites
56 weeks
Total Duration
Researchers are conducting a study comparing two surgical methods for bladder cancer patients requiring urinary diversion after radical removal of the bladder. The study aims to evaluate the safety and effectiveness of the detaenial sigmoid neobladder, a newer technique preserving intestinal layers, versus the traditional Hautmann ileal neobladder, which uses a longer segment of the ileum. This multicenter randomized controlled trial addresses important concerns about surgical complexity, intestinal function, and quality of life outcomes. The study involves two groups one receiving the detaenial sigmoid neobladder, which uses a 15 cm segment of sigmoid colon with selective layer removal to form a U shaped reservoir, and the other receiving the Hautmann ileal neobladder constructed from a 70 cm segment of terminal ileum arranged in an M or W shape. Both procedures connect the new bladder to the urethra and ureters using specialized techniques. The study includes follow-up visits at 3-month intervals for the first year and every 6 months for up to 5 years, with imaging and functional assessments performed regularly. Participants undergo regular evaluations including renal ultrasound, biochemical tests, urine cultures, pelvic CT scans, retro-cystograms, urodynamic studies, and cystoscopic examinations. Researchers monitor complications, urinary continence, renal function using the CKD-EPI equation, infections, surgical re-interventions, cancer recurrence, and overall survival. The main outcome measured is residual urine volume in the neobladder at 36 months. Safety and efficacy data collected throughout the follow-up period will help inform future surgical decisions for bladder cancer patients.
CONDITIONS
Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder
A
Abai Xu, doctor
P
Peng Xu, doctor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Zhujiang Hospital
Lead Sponsor
Sun Yat-Sen University Cancer Center
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - Single surgical procedure
Participants undergo either the detaenial sigmoid neobladder or the Hautmann ileal neobladder surgery after bladder removal.
Hospital stay and surgical care
Duration - Up to 5 years
Participants are monitored with regular visits including imaging, urine tests, kidney function assessments, and questionnaires to track recovery and complications.
Visits every 3 months for 1 year, then every 6 months up to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
P Zerhau, M Husár
https://pubmed.ncbi.nlm.nih.gov/16689148/Pierre A Clavien, Jeffrey Barkun, Michelle L de Oliveira...
https://pubmed.ncbi.nlm.nih.gov/19638912/J Alfred Witjes, Eva Compérat, Nigel C Cowan...
https://pubmed.ncbi.nlm.nih.gov/24373477/R E Hautmann, G Egghart, D Frohneberg...
https://pubmed.ncbi.nlm.nih.gov/3336101/Kai Xu, Chun-Xiao Liu, Shao-Bo Zheng...
https://pubmed.ncbi.nlm.nih.gov/23538237/Peter Bacchetti, Jacqueline M Leung
https://pubmed.ncbi.nlm.nih.gov/12357184/Steven A Julious
https://pubmed.ncbi.nlm.nih.gov/15195324/G Haupt, J Pannek, H J Knopf...
https://pubmed.ncbi.nlm.nih.gov/2388342/Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal
https://pubmed.ncbi.nlm.nih.gov/26742998/Hideaki Miyake, Junya Furukawa, Iori Sakai...
https://pubmed.ncbi.nlm.nih.gov/22153716/Zhujiang Hospital
Lead Sponsor
Sun Yat-Sen University Cancer Center
Collaborating Sponsor